C81.24 Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb

Name of the Condition

• Mixed Cellularity Hodgkin Lymphoma, Lymph Nodes of Axilla and Upper Limb (ICD-10: C81.24)

Summary

Mixed cellularity Hodgkin lymphoma is a subtype of Hodgkin lymphoma characterized by a heterogeneous mix of cell types within affected lymph nodes. It is one of the classical Hodgkin lymphoma subtypes, distinguished by the presence of Reed-Sternberg cells and a variable inflammatory background. This subtype typically presents with widespread lymph node involvement and may affect other lymphoid tissues or organs. The "lymph nodes of axilla and upper limb" designation specifies the anatomical location of the lymphoma.

Causes

The exact cause of mixed cellularity Hodgkin lymphoma is not fully understood, but it is associated with genetic mutations and immune system dysregulation. Epstein-Barr virus (EBV) infection is frequently linked to this subtype, suggesting a potential role in its development. Other contributing factors may include genetic predisposition and environmental exposures, though specific triggers remain under investigation.

Risk Factors

• Age: Most common in adults, with a peak incidence in the 30-50 age range.
• Gender: Slightly more prevalent in males.
• Epstein-Barr virus infection: Prior exposure increases risk.
• Immune system suppression: Conditions like HIV/AIDS or immunosuppressive therapy may elevate susceptibility.
• Family history: A first-degree relative with lymphoma may increase risk.

Symptoms

• Painless swelling of lymph nodes in the axilla or upper limb
• Fever, night sweats, or unexplained weight loss (B symptoms)
• Fatigue or general malaise
• Pruritus (itching) in some cases

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans), and biopsy of the affected lymph node. Histopathological examination confirms the presence of Reed-Sternberg cells and the mixed cellularity pattern. Staging procedures assess the extent of disease to guide treatment planning.

Treatment Options

Treatment depends on the stage and may include chemotherapy, radiation therapy, or a combination of both. Immunotherapy or targeted therapies may be considered in certain cases. Treatment plans are individualized based on patient factors and disease characteristics.

Prognosis and Follow-Up

Prognosis varies by stage and patient response to treatment. Early-stage disease generally has a favorable outcome with standard therapies. Regular follow-up is essential to monitor for recurrence or late effects of treatment, including imaging and clinical assessments.

Complications

• Disease progression or recurrence
• Treatment-related side effects (e.g., infection risk, organ toxicity)
• Secondary malignancies in rare cases
• Lymphedema (swelling) in the affected limb

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known environmental exposures linked to lymphoma risk, if applicable.
• Follow recommended screening for high-risk individuals (e.g., those with EBV or immune suppression).

When to Seek Professional Help

Seek medical attention for persistent lymph node swelling, unexplained weight loss, fever, or night sweats. Prompt evaluation is important for early diagnosis and treatment.

Tips for Medical Coders

Code C81.24 is specific to mixed cellularity Hodgkin lymphoma involving the lymph nodes of the axilla and upper limb. Ensure documentation supports the anatomical location and histological subtype. Verify that the code aligns with the clinical findings and avoid using this code for unspecified or other site locations.